Know Cancer

or
forgot password

Factor VIII Inhibitor Formation: Identifying Predisposing Genetic Factors


N/A
N/A
N/A
Not Enrolling
Both
Hemophilia

Thank you

Trial Information

Factor VIII Inhibitor Formation: Identifying Predisposing Genetic Factors


In collaboration with investigators of the Hemophilia Inhibitor Genetic Study (HIGS)
multicenter study and the University of Lund, University Hospital, Malmo, Sweden, we propose
to assess the role of genetic variants in the process of developing inhibitors to Factor
VIII in persons with hemophilia. The discovery of genetic associations offers the potential
to direct clinical management in order to prevent inhibitor development and improve clinical
care in patients with inhibitors.

Inclusion Criteria


- INCLUSION CRITERIA

DNA and relevant clinical data from properly consented hemophiliac subjects and family
members (maximum estimated = 3500) will be provided to the LGD for genotyping and
analysis.

EXCLUSION CRITERIA

No available subjects will be excluded to maximize power.

Type of Study:

Observational

Study Design:

N/A

Principal Investigator

Janelle Cortner, Ph.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

999905160

NCT ID:

NCT00344435

Start Date:

May 2005

Completion Date:

Related Keywords:

  • Hemophilia
  • Hemophilia
  • Antibody
  • Mutations
  • SNP
  • clotting
  • Hemophilia A

Name

Location